Broad-Spectrum Effects of 4-Aminopyridine to Modulate Amyloid β1–42-Induced Cell Signaling and Functional Responses in Human Microglia
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
We investigated the modulating actions of the nonselective K+channel blocker 4-aminopyridine (4-AP) on amyloid β (Aβ 1–42)-induced human microglial signaling pathways and functional processes. Whole-cell patch-clamp studies showed acute application of Aβ 1–42(5 μ m) to human microglia led to rapid expression of a 4-AP-sensitive, non-inactivating outwardly rectifying K+current (IK). Intracellular application of the nonhydrolyzable analog of GTP, GTPγS, induced an outward K+current with similar properties to the Aβ 1–42-induced IK including sensitivity to 4-AP (IC 50= 5 m m). Reverse transcriptase-PCR showed a rapid expression of a delayed rectifier Kv3.1 channel in Aβ 1–42-treated microglia. Aβ 1–42 peptide also caused a slow, progressive increase in levels of [Ca 2+]i(intracellular calcium) that was partially blocked by 4-AP. Chronic exposure of human microglia to Aβ 1–42 led to enhanced p38 mitogen-activated protein kinase and nuclear factor κB expression with factors inhibited by 4-AP. Aβ 1–42 also induced the expression and production of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor-α, the chemokine IL-8, and the enzyme cyclooxygenase-2; 4-AP was effective in reducing all of these pro-inflammatory mediators. Additionally, toxicity of supernatant from Aβ 1–42-treated microglia on cultured rat hippocampal neurons was reduced if 4-AP was included with peptide.In vivo, injection of Aβ 1–42 into rat hippocampus induced neuronal damage and increased microglial activation. Daily administration of 1 mg/kg 4-AP was found to suppress microglial activation and exhibited neuroprotection. The overall results suggest that 4-AP modulation of an Aβ 1–42-induced IK(candidate channel Kv3.1) and intracellular signaling pathways in human microglia could serve as a therapeutic strategy for neuroprotection in Alzheimer's disease pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 2×
“These include RAGE (receptor of advanced glycation end products) (Yan et al., 1996), scavenger receptor class-A (El Khoury et al., 1996), serpin enzyme complex (Boland et al., 1996), formyl peptide receptor (Lorton et al., 2000), and a cell surface complex composed of integrin and…”
BackgroundAmyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370 · cited 1×
“Alzheimer’s disease (AD), a neurodegenerative disorder exhibiting a gradual decline in cognitive function, is characterized by the presence of neuritic plaques composed of neurofibrillary tangles and amyloid (A ) peptide (Hardy, 1997; Selkoe, 2001).”
BackgroundCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 1×
“Statistically significant correlations between A 1– 42 deposition and cognitive impairment have been established in AD brain (Naslund et al., 2000).”
BackgroundScavenger receptor-mediated adhesion of microglia to β-amyloid fibrils
Khoury, J. E., Hickman, S. E., Thomas, C. A., Cao, L., Silverstein, S. C., & Loike, J. D. (1996) · Nature · doi:10.1038/382716a0 · Cited by 727 · cited 1×
“These include RAGE (receptor of advanced glycation end products) (Yan et al., 1996), scavenger receptor class-A (El Khoury et al., 1996), serpin enzyme complex (Boland et al., 1996), formyl peptide receptor (Lorton et al., 2000), and a cell surface complex composed of integrin and…”
BackgroundCombs, C. K., Karlo, J. C., Kao, S.-C., & Landreth, G. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01179.2001 · Cited by 721 · cited 1×
“The inhibitory effects of 4-AP on A 1– 42-induced NF- B activation could account for the effects of this nonselective K channel blocker to reduce inflammatory mediators released from activated microglia (Combs et al., 2001).”
BackgroundA Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation
Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., & Landreth, G. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02665.2003 · Cited by 501
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Weldon, D. T., Rogers, S. D., Ghilardi, J. R., Finke, M. P., Cleary, J. P., O’Hare, E., Esler, W. P., Maggio, J. E., & Mantyh, P. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-06-02161.1998 · Cited by 348
Microglia, amyloid and dementia in Alzheimer disease
Arends, Y. M., Duyckaerts, C., Rozemuller, J. M., Eikelenboom, P., & Hauw, J.-J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00094-4 · Cited by 139
Choi, H. B., Khoo, C., Ryu, J. K., Van Breemen, E., Kim, S. U., & McLarnon, J. G. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01122.x · Cited by 82 · cited 2×
“The effects of stimuli on phosphorylated p38 MAPK (phospho-p38 MAPK), NF- B, and cyclooxygenase-2 (COX-2) in human microglia were determined using immunocytochemical procedures described previously (Nakajima et al., 1998; Tikka and Koistinaho, 2001; Choi et al., 2002).”
MethodSelf-citation
Cited by
TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function
Zhao, Y., Wu, X., Li, X., Jiang, L.-L., Gui, X., Liu, Y., Sun, Y., Zhu, B., Piña-Crespo, J. C., Zhang, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.031 · Cited by 763
Ryu, J. K., & McLarnon, J. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00434.x · Cited by 406
“A midline skin incision was made in the scalp to expose the skull and stereotaxic unilateral injection of amyloid- (A ) peptide was performed as previously described [14, 15].”
MethodSelf-citationAstrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Li, C., Zhao, R., Gao, K., Wei, Z., Yaoyao Yin, M., Ting Lau, L., Chui, D., & Cheung Hoi Yu, A. (2011) · Current Alzheimer Research · doi:10.2174/156720511794604543 · Cited by 289
Avignone, E., Ulmann, L., Levavasseur, F., Rassendren, F., & Audinat, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1820-08.2008 · Cited by 287
Maezawa, I., Zimin, P. I., Wulff, H., & Jin, L.-W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.135244 · Cited by 278
Metadata
- Authors
- Franciosi, S., Ryu, J. K., Choi, H. B., Radov, L., Kim, S. U., & McLarnon, J. G.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-11-08
- Volume
- 26
- Issue
- 45
- Pages
- 11652-11664
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2066226701
- Cited by
- 68
- References
- 10
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.